-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Uterine Cancer Drug Details: Monoclonal antibody is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EXS-617 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EXS-617 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EXS-617 in Pancreatic Cancer Drug Details: EXS-617 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07799544 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07799544 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07799544 in Metastatic Melanoma Drug Details: PF-07799544 (ARRY-134) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-9592 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-9592 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-9592 in Solid Tumor Drug Details: AZD-9592 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zolbetuximab in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Oropharyngeal Cancer Drug Details: Tislelizumab (Baizean, Tevimbra, Tizveni) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Gastric Cancer Drug Details: Enfortumab vedotin (Padcev)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enfortumab Vedotin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enfortumab Vedotin in Non-Small Cell Lung Cancer Drug...